1. Home
  2. EVTL vs CTNM Comparison

EVTL vs CTNM Comparison

Compare EVTL & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertical Aerospace Ltd.

EVTL

Vertical Aerospace Ltd.

HOLD

Current Price

$3.92

Market Cap

607.7M

Sector

Industrials

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$13.18

Market Cap

507.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVTL
CTNM
Founded
2016
2009
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Aerospace
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
607.7M
507.0M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
EVTL
CTNM
Price
$3.92
$13.18
Analyst Decision
Strong Buy
Buy
Analyst Count
7
5
Target Price
$13.20
$19.80
AVG Volume (30 Days)
669.5K
201.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.76
$3.35
52 Week High
$7.60
$16.33

Technical Indicators

Market Signals
Indicator
EVTL
CTNM
Relative Strength Index (RSI) 39.78 43.17
Support Level $3.71 $10.39
Resistance Level $4.70 $16.17
Average True Range (ATR) 0.21 1.17
MACD 0.01 -0.26
Stochastic Oscillator 32.59 15.58

Price Performance

Historical Comparison
EVTL
CTNM

About EVTL Vertical Aerospace Ltd.

Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero operating emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: